Genes mutated in congenital malformation syndromes are frequently implicated in oncogenesis 1,2 , but the causative germline and somatic mutations occur in separate cells at different times of an organism's life. Here we unify these processes to a single cellular event for mutations arising in male germ cells that show a paternal age effect 3 . Screening of 30 spermatocytic seminomas 4,5 for oncogenic mutations in 17 genes identified 2 mutations in FGFR3 (both 1948A>G, encoding K650E, which causes thanatophoric dysplasia in the germline) 6 and 5 mutations in HRAS. Massively parallel sequencing of sperm DNA showed that levels of the FGFR3 mutation increase with paternal age and that the mutation spectrum at the Lys650 codon is similar to that observed in bladder cancer 7, 8 . Most spermatocytic seminomas show increased immunoreactivity for FGFR3 and/or HRAS. We propose that paternal age-effect mutations activate a common 'selfish' pathway supporting proliferation in the testis, leading to diverse phenotypes in the next generation including fetal lethality, congenital syndromes and cancer predisposition.
Spontaneous germline point mutations in humans occur at average rates of 4-160 × 10 −9 per nucleotide; tend to be paternal in origin, with a male-to-female mutation ratio of between 2:1 and 7:1; and show only a modest effect of parental age on mutation rate [9] [10] [11] [12] [13] . However, a different pattern is evident in some congenital disorders, which arise from specific point mutations that are two to three orders of magnitude more common than expected. The causative mutations nearly always originate from the healthy fathers (male-to-female ratio >10:1), who, on average, are 2-6 years older than the population mean. We term mutations with these collective properties 'paternal age-effect mutations': the best-documented examples occur in the genes FGFR2, FGFR3, HRAS, PTPN11 and RET (Supplementary Table 1) [14] [15] [16] [17] [18] [19] . In all cases the mutations show dominant inheritance and encode missense substitutions with gain-of-function properties.
The pathological basis of paternal age-effect mutations needs to be explained in the context of normal spermatogenesis, in which progeny of diploid stem cells (spermatogonia) have a choice either to self-renew or to differentiate through a series of mitotic and meiotic divisions, leading to mature sperm 20 . Among paternal age-effect mutations, the properties of the 755C>G transversion in FGFR2 (a cause of Apert syndrome) 14 have been investigated in most detail. A quantitative assay showed that the mutation level is elevated (10 −6 -10 −4 ) in the sperm of many healthy men compared to the background germline rate, and increases with age 21 . However, the mutation levels are usually distributed very unequally between the two FGFR2 alleles, a pattern that is inconsistent with the notion that the mutations originate from many independent replication errors during spermatogenesis. Instead, rare initial mutations could become enriched because of a selective advantage, leading to progressive clonal expansion of the mutant spermatogonia and accounting for the allelic skewing and paternal age effect 21, 22 . Putative FGFR2-mutant clones have been observed in normal testes, as predicted 23 . Additional analyses of sperm and testes for a different Apert syndrome-associated FGFR2 mutation 24, 25 , as well as an FGFR3 mutation that causes achondroplasia [26] [27] [28] , support a shared mechanism for the origin of paternal age-effect disorders.
The proposed clonal expansions of spermatogonia are reminiscent of the action of oncogenes in neoplasia; consistent with this, somatic FGFR2 mutations identical to those causing Apert syndrome are frequent in endometrial carcinoma 29, 30 . We therefore proposed that the mutant clones in the testis might themselves progress to testicular tumors 31 . Previous attempts to identify FGFR2 or FGFR3 mutations in common testicular germ cell tumors (seminomas and non-seminomas) yielded negative results 31, 32 ; however, these tumors occur predominantly in young men (aged 25-35 years) and arise from a fetal precursor state 33 , which is difficult to reconcile with the proposed origin of paternal age-effect mutations. Here we have investigated spermatocytic seminomas, a rare type of testicular germ cell tumor with a later mean age of onset (~54 years). These tumors present as slow-growing, well-circumscribed swellings that rarely metastasize and are thought to originate from the adult spermatogonial lineage 4, 5 .
We sequenced mutation hot spots in fibroblast growth factor receptor genes (FGFR1, FGFR2 and FGFR3) in 30 spermatocytic seminomas (Supplementary Fig. 1a) . In both cases, histopathologically normal testis adjacent to the tumor did not carry the mutation. This mutation has previously been identified in the germline heterozygous state in the neonatally lethal skeletal disorder thanatophoric dysplasia type II (MIM187601) 6 and as a somatic mutation in bladder tumors 7, 8 , seborrheic keratoses 34 and multiple myeloma 35 (Supplementary Table 3 ). The FGFR3 K650E substitution is strongly activating, allowing constitutive autophosphorylation of the intracellular tyrosine kinase domain in the absence of ligand (Supplementary Note) 36, 37 . A paternal age effect in thanatophoric dysplasia was described previously, but genetic studies were not undertaken 38, 39 .
Based on the birth prevalence of thanatophoric dysplasia (which is caused by several different FGFR3 mutations) 6,27 of 2.4 × 10 −5 (refs. 38,39) and by analogy with other FGFR2 and FGFR3 mutations [21] [22] [23] [24] [25] [26] [27] [28] , we expected the 1948A>G mutation to be present at average levels of ~10 −5 in sperm. Because five other point mutations of the FGFR3 Lys650 codon (AAG) have been described in germline congenital disorders 36, 40, 41 and three of these also as somatic mutations in tumors 8, 34, 35, 42 (Fig. 1a, Supplementary Table 3) , we aimed to quantify all nine possible substitutions at FGFR3 codon 650. We divided each DNA sample into three aliquots, two of which were spiked with different amounts of diluted genomic DNA heterozygous for the FGFR3 1948A>C substitution, to provide an internal standard for absolute quantification of mutation levels. Samples were digested with BpiI (recognition sequence GAAGAC) to enrich equally for all FGFR3 Lys650 codon substitutions. During subsequent PCR amplification, we used primers containing unique 4-nucleotide tags to identify each sample, and then pooled all products for a given spike level to construct three independent libraries for massively parallel sequencing (Fig. 1b) .
To assess the accuracy and reproducibility of the assay, we estimated mutation levels for two different FGFR3 Lys650 substitutions (1948A>G (two samples) and 1949A>T) when progressively diluted Figure 1 Strategy used to quantify mutation levels at the FGFR3 Lys650 codon. (a) DNA sequence around the Lys650 codon, the relative positions of XbaI and BpiI restriction enzyme sites used for selection, the PCR primers used for amplification (black arrows, first set of PCR primers; orange arrows, nested PCR primers), the nine potential single nucleotide substitutions of the Lys650 codon (located at cDNA position [1948] [1949] [1950] and the associated germline defects. HCH, hypochondroplasia; TDII, thanatophoric dysplasia type II; Fam AN, familial acanthosis nigricans; SADDAN, severe achondroplasia with developmental delay and acanthosis nigricans; −, not reported as germline mutation. * indicates that the change has also been reported as a somatic mutation in cancer (supplementary table 3 ). Note that all substitutions at the Lys650 codon abolish the BpiI recognition site (pink box) and hence are selected by digestion with this enzyme. (b) Flow diagram summarizing the strategy adopted for quantification of mutation levels using tagged-oligonucleotide pooled PCR and massively parallel sequencing (see also supplementary 
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with normal blood DNA. For both 1948A>G samples we found an excellent correspondence between the amount of input DNA and the estimated mutation level, at least down to an input concentration of 3 × 10 −6 . For the 1949A>T sample, mutation levels were underestimated by a factor of ~3.3-fold but were also strongly correlated with the amount of input DNA (Fig. 2a) .
We estimated levels of the 9 possible single nucleotide substitutions at the FGFR3 Lys650 codon in 78 sperm and 8 blood samples obtained from healthy donors. Whereas relatively low counts of all mutations were found in the blood samples, levels of the 1948A>G substitution were often much higher (maximum of 2.1 × 10 −4 ) in sperm samples and were significantly correlated with donor age (Spearman's rank r s = 0.34, P = 0.002) (Fig. 2b) . 1948A>G was the most prevalent substitution in 66/78 sperm donors ( Fig. 2c; Supplementary  Table 4 ) and accounted for 73% of total mutations in these samples. Among the other potential substitutions, 1949A>C (K650T) accounted for 17% of total mutations in sperm and was the most prevalent mutation in 8/78 samples. This change has been described as a constitutional mutation in a few individuals with acanthosis nigricans and mild short stature 41 and as a somatic mutation in bladder tumors 42 (Supplementary Table 3) . The three other substitutions that accounted for total mutation levels >1%, 1949A>T (K650M) and 1950G>C/T (K650N), have also been observed in constitutional disorders (Fig. 1a, Supplementary Table 3 ) 36, 40 . By contrast, the three point mutations that encode silent, conservative or stop changes (Fig. 1a) , which have not been reported as either germline or somatic mutations, were all >1,000-fold less prevalent than 1948A>G.
The variation in prevalence of different mutations at the Lys650 codon, and correspondence with the functional effect of the encoded substitution, suggest differential selection of cells expressing mutant proteins. We compared the average levels in sperm of the nine FGFR3 Lys650 point mutations with four other measurements for this codon (Fig. 2d, Supplementary Table 3 ). There was a strong correlation (r = 0.95) with the total number of cases reported of each germline mutation, indicating that the level of mutations in sperm is likely to be the major determinant of the population prevalence of different pathogenic germline mutations. There was also a strong correlation (r = 0.94) with the total cases reported of each somatic mutation in bladder tumors, suggesting that the Lys650-mutant sperm are produced by an oncogenic process. The correlations were substantially weaker with the mutation distribution observed in seborrheic keratoses (r = 0.33) and with the relative activation potential of the tyrosine kinase measured by in vitro assay (r = 0.27) 36 : in both contexts, the gain-of-function effect of the K650M mutation appears to surpass that of K650E (Fig. 2d) . However, heterozygosity for K650M, or for the equivalent K644M mutation in mouse Fgfr3, leads to a viable phenotype in both species 40, 43 , whereas K650E (K644E in mouse) is lethal 6, 44 , which demonstrates that the in vitro kinase measurement does not capture all dimensions of the pathological consequences of these two substitutions (see Supplementary Note).
We screened 14 additional genes in the spermatocytic seminomas, including (i) genes mutated in syndromes exhibiting a strong paternal age effect (HRAS, PTPN11, RET); (ii) genes involved in the signal transduction pathways (mitogen-activated protein kinase (MAPK) and the phosphoinositide-3 kinase (PI3K)) of proteins encoded by class (i) genes and for which pathogenic activating mutations have been reported (AKT1, BRAF, KRAS, MAP2K1, MAP2K2, NRAS, PIK3CA, SOS1); and (iii) genes for which oncogenic mutations are commonly found in tumors (bladder, thyroid and endometrial cancers) in which paternal age-effect mutations have also been described (CTNNB1, EGFR, KIT). Five mutations (all in tumors negative for FGFR3 mutations) were found in HRAS at the Gln61 codon; three were 182A>G (Q61R) transitions and two were 181C>A (Q61K) transversions. All mutations were apparently homozygous, and they were absent in adjacent normal tissue in the four available cases (Supplementary Fig. 1b ). Q61R and Q61K substitutions are common in human cancers (Catalogue of Somatic Mutations in Cancer: http://www.sanger.ac.uk/perl/genetics/CGP/cosmic) and are both highly activating in a transformation assay 45 . In the germline, heterozygous HRAS mutations cause Costello syndrome 48 , whereas HRAS is found in the nucleus of some basal spermatogonia and in the cytoplasm of primary spermatocytes and round spermatids at the tubular lumen (scale bars, 50 µm).
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volume 41 | number 11 | november 2009 Nature GeNetics l e t t e r s (MIM218040) 16, 17, 46 , but no substitution at Gln61 has been identified, which is likely to reflect lethality of these mutations 17, 45, 47 (see Supplementary Note). No mutations were identified in the other 13 genes screened (Supplementary Table 2 ). The average age of subjects with spermatocytic seminomas who were positive for FGFR3 or HRAS mutations (74.9 years) was significantly greater than for those who were mutation negative (57.6 years) (Student's t-test P = 0.0009) (Fig. 3a) .
To evaluate further the role of FGFR3 and HRAS in spermatocytic seminomas, we examined protein distribution in 26 tumors, including all 7 mutation-positive tumors. FGFR3 (ref. 48 ) and HRAS are expressed in subpopulations of cells in normal seminiferous tubules (Fig. 3b insets) . pERK1/2, an activated effector of the MAPK pathway (Fig. 4a) , is present in the nucleus of a subset of spermatogonia, in primary spermatocytes and in a subset of round spermatids (data not shown). In spermatocytic seminomas, we found strong positive staining for FGFR3 in 5/24 tumors (including 1/2 that were FGFR3 mutation positive) and for HRAS in 15/26 tumors (including 4/5 that were HRAS mutation positive) (Fig. 3b) ; 18/26 (70%) of tumors were strongly positive for one or both proteins. In most tumors (18/24), including 6/7 mutated cases, the presence of FGFR3 and HRAS was mutually exclusive, but this did not show a simple correlation with the gene mutated in the mutation-positive cases (Fig. 3b) . pERK1/2 was detected in 14/25 (56%) of tumors (Supplementary Table 2) .
Our results support the proposal 31 that clonal expansion resulting from selective advantage of paternal age-effect mutations can lead to testicular tumors. To our knowledge our work links for the first time in any organism the processes of mutation in the soma (causing neoplasia) and germline (causing heritable disorders in the next generation), which normally occur in different cells, to a mutational event likely happening in the same cell. The clonal expansions presumably involve altered dynamics of stem cell self-renewal, through a proliferative advantage (possibly enhanced by preferential survival) 49 compared to neighboring non-mutant cells, analogous to the role of oncogenes in cancer. Only weak advantage (selection coefficient of 0.002-0.01 per cell generation) 3,23,24 is necessary to account for the observed mutation levels in sperm and the paternal-age excess (2-6 years) observed for the associated germline disorders. Our data favor a premeiotic origin 4, 5 for spermatocytic seminoma, which is supported by the observation that transfection of mouse spermatogonial stem cells with mutant HRAS (encoding a G12V substitution) causes seminomatous tumors 50 . Men originating tumors containing FGFR3 and HRAS mutations were significantly older than those without such mutations (Fig. 3a) , suggesting that the mutated tumors represent a distinct pathological subset.
These and previous data [21] [22] [23] [24] [25] [26] [27] [28] indicate that activating mutations in FGFR2, FGFR3 and HRAS promote clonal expansion in the testis. The encoded proteins are physiologically connected, as HRAS lies downstream of FGFRs in the growth factor/receptor signaling pathway (Fig. 4a) 2, 46 . By considering the additional genes (RET and PTPN11) known to be subject to paternal age-effect mutations (Supplementary Table 1 ), these connections can be extended. Thus, RET, like the FGFRs, is a receptor tyrosine kinase (RTK) that signals through RAS and is crucial in spermatogonial renewal 51 . Overexpression of GDNF, the RET ligand, leads to accumulation of undifferentiated spermatogonia and testicular tumors in older mice 52 . PTPN11 (encoding SHP2) positively regulates RTK-RAS signaling (Fig. 4a) 53 .
A central role for abnormal FGFR3-RAS signaling in the origin of spermatocytic seminoma is supported by the immunohistochemical analysis (Fig. 3b) . Both FGFR3 and RAS are present in normal (a) Simplified depiction of components of the growth factor receptor-RAS-MAPK signaling pathway (ovals) and associated congenital disorders (boxes). The disorders and proteins for which a paternal age effect has been documented for mutations in the associated gene are labeled in blue; red highlights those cases for which there is additional experimental evidence for increased levels of causative mutations in testes. CFC, cardio-faciocutaneous syndrome; MEN, multiple endocrine neoplasia; RTK, receptor tyrosine kinase; TD, thanatophoric dysplasia. (b) Proposed consequences of mutations depending on the degree of mutant protein activation. The original mutations are rare events that occur randomly in spermatogonial stem cells or progenitors. Strongly activating mutations (left column), such as FGFR3 K650E, lead over time to the formation of large clones within the testis (red ovals), potentially (with additional mutational events) causing spermatocytic seminomas. The high relative enrichment increases the risk of fertilization by mutant sperm, causing lethal germline phenotypes such as thanatophoric dysplasia. For moderately activating mutations (central column), absence of mutations in spermatocytic seminoma suggests that clonal expansions (orange ovals) occur to a lesser degree and are more likely to be self-limiting. These mutations lead to classical congenital disorders. For weakly activating mutations (right, yellow ovals), the limited clonal expansions would be undetectable using current experimental methods but could contribute to an increased burden of many new, potentially oncogenic, mutations in the next generation. l e t t e r s testis but show markedly elevated staining in most spermatocytic seminomas, including those lacking FGFR3 and HRAS mutations (in which other mechanisms are presumably causing upregulation of the proteins). The reciprocal pattern of increased FGFR3 or HRAS staining in many tumors suggests that elevation of either component is sufficient for pathway activation. Similar observations have been made in low-grade bladder cancer, in which mutations in FGFR3 and RAS genes are mutually exclusive 54 and FGFR3 mutation status and protein expression do not always correlate 8 . The spectrum of FGFR3 Lys650 codon mutations in sperm is very similar to that in bladder cancer (Fig. 2d) , suggesting that similar mutation-selection mechanisms operate in these distinct cellular contexts.
RAS activates multiple pathways, including those typically involved in proliferation (MAPK) and survival (PI3K) 2 . Activating mutations of genes encoding downstream components of the MAPK pathway (BRAF, RAF1, MEK1 and MEK2), cause neuro-cardio-facial-cutaneous syndromes that overlap with those resulting from PTPN11 and HRAS mutations (Fig. 4a) 2, 46 ; inhibition of the MAPK pathway in mice carrying specific Fgfr2 and Ptpn11 mutations ameliorates their abnormal phenotypes 55, 56 . In 56% of spermatocytic seminomas we observed pERK1/2 staining, indicating pathological activation of the MAPK pathway (Supplementary Table 2 ). However, the PI3K pathway has also been functionally implicated in spermatogonial self-renewal 50 .
We envisage a range of consequences for these selfish 27 mutations occurring in spermatogonial cells (Fig. 4b) . Heterozygosity for the most highly activating mutations, such as FGFR3 K650E and HRAS Q61R/K, causes severe, lethal phenotypes when transmitted in the germline 6, 17 . Additional secondary genetic changes at these loci (Supplementary Note) would lead, in combination with other mutations 57 , to spermatocytic seminoma. Moderately activating mutations, for example those encoding substitutions at Gly12 or Gly13 in HRAS (Costello syndrome) 16, 17, 46 , in FGFR2 (Apert syndrome) 14, [21] [22] [23] [24] [25] and in FGFR3 (achondroplasia) 15, 26, 28 , lead to clonal expansion that is eventually limited by growth arrest or senescence 58 before overt tumors become apparent. We view this process as analogous to that occurring in skin, where a spectrum of activating FGFR3 mutations in keratinocytes leads to seborrheic keratoses 34 . Diverse mutations in spermatogonia that confer weaker selective advantage may lead to lower levels of enrichment (>1-50-fold) in sperm. As well as encoding missense substitutions, mutations could confer altered gene expression, which shows a high fraction of positively selected changes in testis 59 . Such subtle effects would be technically challenging to detect, yet could contribute substantially to the burden of human disease, through a common disease-rare variant mechanism 60 . Cancer-predisposing mutations are especially likely to be favored by this process, posing an increased risk to offspring of older fathers.
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Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/. Accession codes. GenBank: FGFR3 genomic DNA, NT_006081; FGFR3 exon IIIc cDNA, NM_000142; HRAS cDNA, NM_005343. cDNA numbering is given relative to the A (= 1) of the ATG initiation codon; note that the FGFR3 Lys650 (K650) codon is alternatively numbered Lys652 (K652) in the exon IIIb spliceform. slice of the expected size (137 bp) was excised, purified (E.Z.N.A. gel purification kit) and resuspended in 25 µl sterile water. Each library was then enriched by a final amplification (Gex PCR) using 1.5 µl of purified ligated products. The three libraries were prepared independently to avoid cross-contamination and were quantified using a fluorometer (Qubit) before being validated by direct sequencing, pyrosequencing (Biotage) and Bioanalyzer (Agilent).
Massively parallel sequencing of the libraries was performed on three different channels of an Illumina GAII sequencer by ServiceXS (Leiden, The Netherlands) for 36 cycles using the Gex-DpnII sequencing primer (Supplementary Fig. 2b ).
Estimation of mutation levels from Illumina GAII sequencing data. To estimate the levels of each single nucleotide mutation at the FGFR3 Lys650 codon (corresponding to cycles 23-25 of the Illumina sequencing scheme; Supplementary Fig. 2b ), we used a Bayesian approach to fit a model to the observed counts at each nucleotide in the sequencing data that allows for bias in frequencies derived from sequencing error and noise introduced by the rounds of PCR and digestion. The model is similar to that used previously for pyrosequencing 21 , but allows for a different error structure arising from the GAII Illumina technology. We discarded reads where the minimum Phred quality score for any of the four bases of the tag (cycles 1-4), or three bases of the Lys650 codon (cycles [23] [24] [25] , was under 10. We also eliminated reads with apparent frameshift errors or mutations outside the BpiI restriction site (that is, in the invariant 16-nt primer sequence). Let z i be the log 10 frequency of mutation i in the sample. Our prior for z i is normal (−8, 2) for all non-wildtype species. After addition of the spike at concentration s j in experiment j (s 0 = 0, s 1 = 10 −5 , s 2 = 10 −4 ), the normalized frequencies of the non-wild-type mutations are given by where I is an indicator function that takes the value 0 or 1 depending on whether the mutation in question is the same as the HCH1-spike (1948A>C). We allow each experiment (defined by the level of spike and the lane of the machine on which sequencing was carried out) to have separate bias and signal-to-noise ratio parameters. Specifically, we assume that the counts for the mutations in the sequencing data are multinomial with frequency vector where B j represents the signal-to-noise ratio for experiment j and w ij represents the background for mutation i in experiment j. We assume a uniform (0, 1,000) prior for each B j and a uniform(0, 100) prior for each w ij . Through use of the multinomial-Dirichlet model, we can integrate over x to give the contribution to the total likelihood from experiment j in a given sample To estimate parameters, we used Metropolis-Hastings MCMC with sequential update of each parameter, a burn-in period of 3,000 complete parameter updates and a subsequent 10,000 samples. Multiple runs from different starting points were conducted to check for convergence, and visual inspection was used to compare observed to expected values as a means of checking model adequacy. Titration data (Fig. 2a) , normal wild-type control DNA and biological samples were analyzed together. Samples from the chain are summarized by the posterior mean value and the 95% equal-tailed probability interval (ETPI). Estimated levels of all FGFR3 Lys650 codon substitutions for sperm and blood samples are given in Supplementary Table 4. URLs. Digital Gene Expression-Tag Profiling with DpnII, http://illumina.ucr. edu/ht/documentation/molbiol-docs/DGE-DpnII-Sample-Prep.pdf/view.
